MiddleBrook Pharmaceuticals Inc.'s modified liquidation plan became effective Jan. 3, according to court documents (In re MiddleBrook Pharmaceuticals Inc.).
MiddleBrook Pharmaceuticals Inc. was a pharmaceutical company focused on commercializing anti-infective products including PULSYS, which enabled delivery in rapid bursts of certain drugs, MOXATAG, the first and only FDA-approved once-daily amoxicillin, and KEFLEX, the immediate-release brand of cephalexin, according to the company’s website.
Chapter 11 Filing.
The Westlake, Texas-based company filed for Chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware on Apr. 30, 2010 (22 BBLR 643, 5/13/10). On July 28, 2010, the debtor sold ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.